Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]
uniqure
UniQure pulls first gene therapy from market in Europe
The Western world’s 1st gene therapy will not return to the European market after its 5-year conditional approval expires on Oct. 25 this year, according to UniQure (NSDQ:QURE). The company’s Glybera product will only be available for patients who were approved for treatment and reimbursement before Oct. 25, UniQure partner Chiesi said today. “The decision […]
